lanatoside c

Lanatoside C is a cardiac glycoside derived from Digitalis lanata and used primarily for the treatment of certain cardiac arrhythmias such as rapid response atrial fibrillation and paroxysmal supraventricular tachycardia. It can be administered orally or intravenously and is available in generic form in several countries. The drug acts by inhibiting the Na+/K+-ATPase pump on cardiac cell membranes. This inhibition increases intracellular sodium concentration which leads to increased intracellular calcium via the sodium-calcium exchanger; this enhances myocardial contractility (positive inotropy) and modulates electrical conduction through the heart[1][6]. Lanatoside C can also be metabolized into digoxin by deglucosylation[4]. Beyond its cardiovascular uses it has demonstrated anti-cancer activity in preclinical studies through induction of apoptosis (via caspase-dependent and independent pathways), G2/M cell cycle arrest (by blocking MAPK/Wnt/PAM signaling), inhibition of PI3K/AKT/mTOR signaling pathways and activation of protein kinase delta (PKCδ)[5][6][8].

Brand names

CedilanidCeglunatIsolanid

Other names

6-[6-[6-[[12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy -2-methyl -3-[3 ,4 ,5-trihydroxy -6-(hydroxymethyl)oxan -2 -yl ]oxyoxan -4 -yl acetate